Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1607 • ACR Convergence 2023
Autoantibodies to Transcription Factor a Mitochondria Link Mitochondrial Damage and Thrombosis in Systemic Lupus Erythematosus
Eduardo Gomez-Banuelos¹, Alessandra Ida Celia², Maria Isabel Trejo Zambrano³, Merlin Paz³, Erika Darrah³, Daniel Goldman⁴, Michelle Petri⁴ and Felipe Andrade³, ¹The Johns Hopkins University, Baltimore, MD, ²John Hopkins University of Medicine, Rome, Italy, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Upon activation with interferon (IFN) and RNP-immune complexes, defective mitophagy in neutrophils results in the release of mtDNA in complex with transcription factor A…
Abstract Number: 0111 • ACR Convergence 2023
Hippo-YAP1-CCN2 Signaling by Microvascular Endothelial Cells Licenses Vascular Smooth Muscle Cell Proliferation in Antiphospholipid Syndrome
Wenying Liang¹, Allison Billi¹, Srilakshmi Yalavarthi¹, Christine Rysenga¹, Claire Hoy¹, Cyrus Sarosh¹, Yu Zuo¹, Eliza Pei-Suen Tsou¹, Jason Knight¹ and Hui Shi², ¹University of Michigan, Ann Arbor, MI, ²Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Background/Purpose: Some patients with antiphospholipid syndrome (APS) are afflicted by an insidious small-vessel vasculopathy that results in the accrual of organ damage over time. While…
Abstract Number: 1608 • ACR Convergence 2023
Plasma Proteomic Profiling in Antiphospholipid Antibody-positive Patients with Different Clinical Phenotypes: Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Registry
Ayesha Butt¹, Rolando Garcia Milian¹, George Goshua¹, Sean Gu¹, Eugenia Chock², Valentina Restrepo¹, John Hwa¹, Hyung Chun¹, H Michael Belmont³, Kello Nina⁴, D. Ware Branch⁵, Michelle Petri⁶, Jason Knight⁷, Rohan Willis⁸, Maria Laura Bertolaccini⁹, Doruk Erkan¹⁰, Alfred lee¹, Anish Sharda¹ and Alexander Pine¹¹, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Medicine, Greenwich, CT, ³NYU School of Medicine, New York, NY, ⁴Northwell Health, Brooklyn, NY, ⁵University of Utah, Salt Lake City, UT, ⁶Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁷University of Michigan, Ann Arbor, MI, ⁸University of Texas Medical Branch, Galveston, TX, ⁹King's College London, London, United Kingdom, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹VA Connecticut/Yale School of Medicine, West Haven, CT
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with thrombotic and obstetric complications arising via a model of immunothrombosis. Patients may present with a spectrum…
Abstract Number: 0096 • ACR Convergence 2023
Performance Assessment of Lupus Anticoagulant Tests Using Taipan and Ecarin Snake Venom Clotting Times: An International Study from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Core Laboratories
Maria Efthymiou¹, Ian Mackie¹, Rohan Willis², Vittorio Pengo³, Danieli Andrade⁴, Elisa Bison³, Olga Amengual⁵, Zurina Romay-Penabad⁶, Yuichiro Fujieda⁵, Maria Laura Bertolaccini⁷, Doruk Erkan⁸, Hannah Cohen⁹ and On Behalf Of APS ACTION¹⁰, ¹University College London, London, United Kingdom, ²University of Texas Medical Branch, Galveston, TX, ³Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁴University of São Paulo, São Paulo, Brazil, ⁵Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan, ⁶Antiphospholipid Standardization Laboratory, Division of Rheumatology, University of Texas Medical Branch, TX, ⁷King's College London, London, United Kingdom, ⁸Hospital for Special Surgery, New York, NY, ⁹University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁰on behalf of APS ACTION, New York, NY
Background/Purpose: Lupus anticoagulant (LA) test performance is critical for APS diagnosis and management. However, variability remains a challenge in LA testing, particularly in anticoagulated samples,…
Abstract Number: 0112 • ACR Convergence 2023
Molecular Stratification of Antiphospholipid Syndrome Patients Through Integrative Analysis of the Whole-blood RNA Transcriptome
Amala Ambati¹, Feiyang Ma¹, Katarina Kmetova¹, Sherwin Navaz¹, Claire Hoy¹, Cyrus Sarosh¹, Ajay Tambralli¹, Johann E. Gudjonsson¹, J. Michelle Kahlenberg¹, Jacqueline Madison¹, Ali Duarte-Garcia², Jason Knight¹ and Yu Zuo¹, ¹University of Michigan, Ann Arbor, MI, ²Mayo Clinic, Rochester, MN
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease associated with diverse clinical manifestations in the setting of persistent antiphospholipid antibodies (aPL). Early diagnosis and…
Abstract Number: 2324 • ACR Convergence 2023
Leveraging ChatGPT for Real-World Systematic Lupus Erythematosus Data Curation from Electronic Health Records: A Feasibility Study
Lixia Yao, Liwam Gebru, Biruk Aweke, Jay Patel, Ernest Vina, David Fleece and Huanmei Wu, Temple University, Philadelphia, PA
Background/Purpose: Epidemiologists, health services researchers, and health outcome investigators have begun utilizing real-world data (RWD) to gain valuable insights into disease patterns, treatment outcomes, and…
Abstract Number: 0097 • ACR Convergence 2023
Transient Ischemic Attack in Antiphospholipid Antibody-positive Patients: Retrospective and Prospective Results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Jonathan Thaler², Danieli Andrade³, Megan Barber⁴, Maria Tektonidou⁵, Savino Sciascia⁶, Vittorio Pengo⁷, Jose Pardos-Gea⁸, Guillermo Ruiz-Irastorza⁹, Chary Lopez-Pedrera¹⁰, H Michael Belmont¹¹, Kello Nina¹², Paul R. Fortin¹³, Stéphane Zuily¹⁴, Cecilia Chighizola¹⁵, Flavio Victor Signorelli¹⁶, Zhuoli Zhang¹⁷, Tatsuya Atsuma¹⁸, Maria Efthymiou¹⁹, D. Ware Branch²⁰, Cecilia Nalli²¹, Esther Rodriguez almaraz²², Michelle Petri²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Yu Zuo²⁸, Rosana M Quintana²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Doruk Erkan² and On Behalf Of APS ACTION³⁴, ¹SUNY Downstate Medical Center, Brooklyn, NY, ²Hospital for Special Surgery, New York, NY, ³University of São Paulo, São Paulo, Brazil, ⁴University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, ⁵Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁶University of Turin, Torino, Italy, ⁷Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁸Vall d'Hebron University Hospital, Barcelona, Spain, ⁹Hospital Universitario Cruces, Barakaldo, Spain, ¹⁰IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ¹¹NYU School of Medicine, New York, NY, ¹²Northwell Health, Brooklyn, NY, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁴Lorraine University, Vandoeuvre-lès-Nancy, France, ¹⁵University of Milan, Milan, Italy, ¹⁶University of São Paulo, Rio De Janeiro, Brazil, ¹⁷Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁸Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ¹⁹University College London, London, United Kingdom, ²⁰University of Utah, Salt Lake City, UT, ²¹Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, ²²Hospital Universitario 12 de Octubre, Madrid, Spain, ²³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹Centro Regional de Enfermedades Autoinmunes y Reumticas (CREAR), Grupo Oroño, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³University College London Hospitals NHS Foundation Trust, London, United Kingdom, ³⁴on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION Registry aims to study the course of disease in antiphospholipid antibody (aPL)-positive patients. Although transient ischemic attack (TIA) can develop in aPL-positive…
Abstract Number: 0113 • ACR Convergence 2023
Serum Myeloperoxidase (MPO)-DNA Complexes and Serum Calprotectin Differentiate Isolated Thrombotic Antiphospholipid Syndrome from Isolated Obstetric Antiphospholipid Syndrome
Ruyu Liang¹, Ranran Yao², Ziye Wang³, Wenwen Pei², Renge Liang³ and Chun Li⁴, ¹Peking University, XiCheng, China, ²Peking University, Beijing, China, ³Peking University People's Hospital, Beijing, China, ⁴Peking University People’s Hospital, Beijing, China
Background/Purpose: There is a lack of serum markers to differentiate thrombotic APS (tAPS) and obstetric APS (oAPS). Neutrophil extracellular traps (NETs) are involved in the…
Abstract Number: 2454 • ACR Convergence 2023
Endometriosis Increase Risk of Antiphospholipid Syndrome: A Propensity Score Matched Cohort Study
Zhiyong Chen¹, Shiow-Ing Wang², James Cheng-Chung Wei³ and Sheng-Ming Dai¹, ¹Department of Rheumatology and Immunology, Shanghai Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, ²Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung, Taiwan, ³Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan
Background/Purpose: Patients with endometriosis have a variety of autoimmune abnormalities. Our objective was to investigate the risk of incident antiphospholipid syndrome (APS) in patients with…
Abstract Number: 0098 • ACR Convergence 2023
Predictors of Mortality in Antiphospholipid Antibody Positive Patients: Prospective Results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository “Registry”
Yasaman Ahmadzadeh¹, Larry Magder², Zeynep Ozge Ozdemir³, Danieli Andrade⁴, Megan R.W. Barber⁵, Maria Tektonidou⁶, Savino Sciascia⁷, Vittorio Pengo⁸, Ariadna Anunciación-Llunell⁹, Guillermo Ruiz-Irastorza¹⁰, Mª Angeles Aguirre¹¹, Michael Belmont¹², Kello Nina¹³, Paul R. Fortin¹⁴, Denis WAHL¹⁵, Maria Gerosa¹⁶, Guilherme De Jesús¹⁷, Zhuoli Zhang¹⁸, Tatsuya Atsuma¹⁹, Maria Efthymiou²⁰, D. Ware Branch²¹, Angela Tincani²², Esther Rodriguez almaraz²³, Giulia Pazzola²⁴, Ricard Cervera²⁵, Bahar Artim Esen²⁶, Hui Shi²⁷, Jason Knight²⁸, Guillermo Pons-Estel²⁹, Rohan Willis³⁰, Ali Duarte-Garcia³¹, Maria Laura Bertolaccini³², Hannah Cohen³³, Michelle Petri³⁴, Doruk Erkan³⁵ and On Behalf Of APS ACTION³⁶, ¹Roger Williams Medical Center, Providence, RI, ²University of Maryland, Baltimore, MD, ³Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴University of São Paulo, São Paulo, Brazil, ⁵University of Calgary, Calgary, AB, Canada, ⁶Joint Academic Rheumatology Program, First Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece, ⁷University of Turin, Torino, Italy, ⁸Department of Cardiac-Thoracic-Vascular Sciences and Public Health University of Padova, Padova, Italy, ⁹VHIR Vall d'Hebron Institut de Investigación, Barcelona, Spain, ¹⁰Hospital Universitario Cruces, Barakaldo, Spain, ¹¹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹²New York University Langone Medical Center, New York, NY, ¹³Northwell Health, Brooklyn, NY, ¹⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, ¹⁵University of Lorraine, Nancy, France, ¹⁶University of Milan, Milano, Italy, ¹⁷Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁸Peking University First Hospital, Rheumatology and Immunology Department, Beijing, China, ¹⁹Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, ²⁰University College London, London, United Kingdom, ²¹University of Utah, Salt Lake City, UT, ²²Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Gussago, Italy, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy, ²⁵Hospital Clínic de Barcelona, Barcelona, Spain, ²⁶Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²⁷Rijin Hospital, Shanghai, China, ²⁸University of Michigan, Ann Arbor, MI, ²⁹CREAR, Rosario, Argentina, ³⁰University of Texas Medical Branch, Galveston, TX, ³¹Mayo Clinic, Rochester, MN, ³²King's College London, London, United Kingdom, ³³Haemostasis Research Unit, Department of Hematology, University College London, London, United Kingdom, ³⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ³⁵Hospital for Special Surgery, New York, NY, ³⁶on behalf of APS ACTION, New York, NY
Background/Purpose: APS ACTION "Registry" was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 0114 • ACR Convergence 2023
Platelets Are Highly Activated and Could Participate in Immune Abnormality of APS
Yu Shi¹, Xiaofan Luo², Quan Chen³, Jiuliang zhao⁴, Mengtao Li⁴ and xiaofeng Zeng⁵, ¹Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Nankai University, Tianjin, China, ³Nankai University, Beijing, China, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Platelets play a pivotal role in the process of coagulation and other biological process. Studies have shown multiple evidences that platelets are highly activated…
Abstract Number: 0677 • ACR Convergence 2022
Obstructive Sleep Apnea in Primary Antiphospholipid Syndrome Impacts Damage Accrual
Gustavo Balbi¹, Flavio Victor Signorelli², Ana Paula Gandara³, Indira Azam³, Dilson Marreiros³, Luciano Drager³ and Danieli Castro Oliveira de Andrade⁴, ¹Universidade de São Paulo, São Paulo, Brazil, ²Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil, ³University of São Paulo, São Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Obstructive sleep apnea (OSA) has been associated with an increased risk of thrombotic-related events, such as myocardial infarction and cerebrovascular diseases in the general…
Abstract Number: 0693 • ACR Convergence 2022
Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)
Naveen Kumar S K¹, Claire Hoy¹, Srilakshmi Yalavarthi¹, Cyrus Sarosh², Kaitlyn Sabb¹, Christine Rysenga¹, Jacqueline Madison¹, Yu Zuo¹ and Jason S Knight³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Temperance, MI, ³University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: By converting extracellular ATP into homeostatic adenosine, the ectonucleotidases CD39 (ATP to AMP) and CD73 (AMP to adenosine) dictate extracellular purinergic gradients and as…
Abstract Number: 0678 • ACR Convergence 2022
Inpatient Epidemiology, Expenditures and Resource Utilization of Antiphospholipid Syndrome: National Inpatient Sample 2019
Patompong Ungprasert¹, Sunisa Kongkiatkamon², Ben Ponvilawan³, Nuttavut Sumransub⁴ and Paul Kroner⁵, ¹Cleveland Clinic, Cleveland Heights, OH, ²Chulalongkorn University, Bangkok, Thailand, ³Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, ⁴University of Minnesota, Minneapolis, MN, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Little is known about inpatient epidemiology, morbidity, mortality and resource utilization of patients with antiphospholipid syndrome (APS). The purpose of this study is to…
Abstract Number: 0694 • ACR Convergence 2022
Evaluation of the Effect of UCB4470 (anti-mouse FcRn) on Amelioration of Thrombosis in a Mouse Model of Antiphospholipid (aPL)-induced Thrombosis
Maria Laura Bertolaccini¹, Yiannis Ioannou², Helen Neale³, Prakash Saha¹ and Alberto Smith¹, ¹King's College London, London, United Kingdom, ²UCB Biopharma SRL, London, United Kingdom, ³UCB Biopharma SRL, Slough, United Kingdom
Background/Purpose: FcRn (the neonatal Fc receptor) is a receptor expressed by antigen-presenting cells, such as monocytes, macrophages, and dendritic cells, as well as on neutrophils.…

« Previous Page
1
…
7
8
9
10
11
…
23
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].